chloroquine and derivatives - for COVID-19 mild to moderate   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.43 [0.49, 4.21]< 10%2 studies (2/-)25.9 %some concernnot evaluable moderatecrucial-
clinical worsening 0.92 [0.61, 1.38]< 10%1 study (1/-)65.6 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

adverse events 1.02 [0.40, 2.58]< 10%2 studies (2/-)48.3 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 90 90